Uterine Cervix CancerFase 2NCT06331468
Hypofractionated Radiochemotherapy
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
40 estudios de fase 2 reclutando ahora mismo, los actualizados más recientemente primero.
Abrir la página de fase 2 · una lista solo de esos estudios
Triangle is made by Triangle Health, Inc.
Ovario y ginecológicos40 estudios
Uterine Cervix CancerFase 2NCT06331468
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
Uterine LeiomyosarcomaFase 2NCT05649956
Letrozole
Cervical CancerFase 2NCT05838521
Sacituzumab govitecan
Ovarian CancerFase 2NCT04918186Artículos
Durvalumab, BA3011, BA3021, ENB003
Recurrent Endometrial CarcinomaFase 2NCT04469764
Abemaciclib, Anastrozole, Letrozole
Ovarian CancerFase 2NCT06906341
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Ovarian CancerFase 2NCT04606914
mirvetuximab soravtansine (MIRV; IMGN853)
Ovary CancerFase 2NCT05887609
Mirvetuximab Soravtansine-gynx, Olaparib
Cáncer de ovario resistente a platinoFase 2NCT06710288
Gemcitabine, N-803, M-CENK
Ovarian CancerFase 2NCT05952453
Carboplatin, olaparibp, embro
Endometrial CancerFase 2NCT03832361
IMGN853
Ovarian NeoplasmsFase 2NCT04641247
Niraparib
HER2/Neu+ Uterine Serous CarcinomaFase 2NCT02491099Artículos
Afatinib
Platinum-Resistant Fallopian Tube CarcinomaFase 2NCT05538091
Vismodegib, Atezolizumab
Ovarian CancerFase 2NCT05071937
ZEN003694, Talazoparib
Cervical CancersFase 2NCT07022470
3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy